Impax Asset Management Group plc Has $5.93 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Impax Asset Management Group plc raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,643 shares of the biopharmaceutical company’s stock after buying an additional 248 shares during the quarter. Impax Asset Management Group plc’s holdings in Regeneron Pharmaceuticals were worth $5,932,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. QRG Capital Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 4.7% in the third quarter. QRG Capital Management Inc. now owns 23,180 shares of the biopharmaceutical company’s stock worth $24,368,000 after acquiring an additional 1,040 shares during the last quarter. Asset Management One Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 2.2% during the third quarter. Asset Management One Co. Ltd. now owns 56,476 shares of the biopharmaceutical company’s stock valued at $59,370,000 after purchasing an additional 1,213 shares during the last quarter. National Pension Service grew its stake in Regeneron Pharmaceuticals by 17.0% in the third quarter. National Pension Service now owns 223,617 shares of the biopharmaceutical company’s stock valued at $235,075,000 after purchasing an additional 32,457 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its position in Regeneron Pharmaceuticals by 1.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 128,178 shares of the biopharmaceutical company’s stock worth $134,746,000 after purchasing an additional 1,243 shares during the last quarter. Finally, Nvwm LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 14 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.1 %

Shares of REGN opened at $829.43 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a 50-day simple moving average of $1,043.57 and a 200-day simple moving average of $1,039.92. Regeneron Pharmaceuticals, Inc. has a 52 week low of $783.57 and a 52 week high of $1,211.20. The firm has a market capitalization of $91.44 billion, a P/E ratio of 20.53, a P/E/G ratio of 2.90 and a beta of 0.15.

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday. Royal Bank of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, Guggenheim boosted their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,097.25.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.